​
​

Kezar Life Sciences (KZR) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

KZR Stock Forecast

Kezar Life Sciences stock forecast is as follows: an average price target of $17.50 (represents a 133.64% upside from KZR’s last price of $7.49) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

KZR Price Target

The average price target for Kezar Life Sciences (KZR) is $17.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $21.00 to $14.00. This represents a potential 133.64% upside from KZR's last price of $7.49.

KZR Analyst Ratings

Buy

According to 3 Wall Street analysts, Kezar Life Sciences's rating consensus is 'Buy'. The analyst rating breakdown for KZR stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Kezar Life Sciences Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 12, 2022-H.C. Wainwright$21.00$9.76115.16%180.37%
May 04, 2022-Wells Fargo$14.00$7.9476.36%86.92%
Row per page
Go to

The latest Kezar Life Sciences stock forecast, released on Aug 12, 2022 by H.C. Wainwright company, set a price target of $21.00, which represents a 115.16% increase from the stock price at the time of the forecast ($9.76), and a 180.37% increase from KZR last price ($7.49).

Kezar Life Sciences Price Target by Period

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$7.49$7.49$7.49
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Kezar Life Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Kezar Life Sciences's last price of $7.49. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 14, 2024H.C. WainwrightNeutralNeutralHold
Oct 02, 2024H.C. Wainwright-NeutralDowngrade
Oct 01, 2024Cowen & Co.BuyBuyHold
Aug 14, 2024Cowen & Co.BuyBuyHold
Jan 03, 2023Wells FargoOverweightOverweightHold
Jun 28, 2022Wells FargoOverweightOverweightHold
Row per page
Go to

Kezar Life Sciences's last stock rating was published by H.C. Wainwright on Oct 14, 2024. The company gave KZR a "Neutral" rating, the same as its previous rate.

Kezar Life Sciences Financial Forecast

Kezar Life Sciences Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23
Revenue-------------$7.00M
Avg Forecast----$1.67M$1.67M$1.67M$1.67M$1.60M$800.00K$750.00K$666.67K$1.00M$166.67K
High Forecast----$1.67M$1.67M$1.67M$1.67M$1.60M$800.00K$750.00K$666.67K$1.00M$166.83K
Low Forecast----$1.67M$1.67M$1.67M$1.67M$1.60M$800.00K$750.00K$666.67K$1.00M$166.50K
# Analysts----1112311131
Surprise %-------------42.00%

Kezar Life Sciences's average Quarter revenue forecast for Dec 23 based on 3 analysts is $1.00M, with a low forecast of $1.00M, and a high forecast of $1.00M. KZR's average Quarter revenue forecast represents a -85.71% decrease compared to the company's last Quarter revenue of $7.00M (Sep 23).

Kezar Life Sciences EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23
# Analysts----1112311131
EBITDA------------$-28.12M$-25.53M
Avg Forecast----$1.00M$1.00M$1.00M$1.00M$960.00K$480.00K$450.00K$400.00K$600.00K$100.00K
High Forecast----$1.00M$1.00M$1.00M$1.00M$960.00K$480.00K$450.00K$400.00K$600.00K$100.10K
Low Forecast----$1.00M$1.00M$1.00M$1.00M$960.00K$480.00K$450.00K$400.00K$600.00K$99.90K
Surprise %-------------46.87%-255.27%

undefined analysts predict KZR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Kezar Life Sciences's previous annual EBITDA (undefined) of $NaN.

Kezar Life Sciences Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23
# Analysts----1112311131
Net Income------------$-32.26M$-23.10M
Avg Forecast$-224.53M$-219.01M$-213.59M$-208.26M$-160.76M$-161.98M$-170.49M$-178.51M$-199.55M$-229.71M$-233.26M$-243.21M$-276.92M$-260.10M
High Forecast$-224.53M$-219.01M$-213.59M$-208.26M$-160.76M$-161.98M$-170.49M$-159.00M$-136.79M$-229.71M$-233.26M$-243.21M$-241.42M$-260.10M
Low Forecast$-224.53M$-219.01M$-213.59M$-208.26M$-160.76M$-161.98M$-170.49M$-197.31M$-226.10M$-229.71M$-233.26M$-243.21M$-305.32M$-260.10M
Surprise %------------0.12%0.09%

Kezar Life Sciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. KZR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Kezar Life Sciences SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23
# Analysts----1112311131
SG&A------------$5.48M$8.79M
Avg Forecast----$2.60M$2.60M$2.60M$2.60M$2.49M$1.25M$1.17M$1.04M$1.56M$259.71K
High Forecast----$2.60M$2.60M$2.60M$2.60M$2.49M$1.25M$1.17M$1.04M$1.56M$259.97K
Low Forecast----$2.60M$2.60M$2.60M$2.60M$2.49M$1.25M$1.17M$1.04M$1.56M$259.45K
Surprise %------------3.52%33.84%

Kezar Life Sciences's average Quarter SG&A projection for Mar 24 is $1.04M, based on 1 Wall Street analysts, with a range of $1.04M to $1.04M. The forecast indicates a -81.04% fall compared to KZR last annual SG&A of $5.48M (Dec 23).

Kezar Life Sciences EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23
# Analysts----1112311131
EPS------------$-0.44$-0.32
Avg Forecast$-3.08$-3.00$-2.93$-2.85$-2.20$-2.22$-2.34$-2.45$-2.73$-3.15$-3.20$-3.33$-3.80$-3.56
High Forecast$-3.08$-3.00$-2.93$-2.85$-2.20$-2.22$-2.34$-2.18$-1.87$-3.15$-3.20$-3.33$-3.31$-3.56
Low Forecast$-3.08$-3.00$-2.93$-2.85$-2.20$-2.22$-2.34$-2.70$-3.10$-3.15$-3.20$-3.33$-4.18$-3.56
Surprise %------------0.12%0.09%

According to undefined Wall Street analysts, Kezar Life Sciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to KZR previous annual EPS of $NaN (undefined).

Kezar Life Sciences Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
IPSCCentury Therapeutics$1.26$15.001090.48%Buy
STTKShattuck Labs$1.11$12.00981.08%Hold
NGMNGM Biopharmaceuticals$1.54$16.50971.43%Buy
NKTXNkarta$2.50$21.60764.00%Buy
HOWLWerewolf Therapeutics$1.64$12.00631.71%Buy
LYELLyell Immunopharma$1.03$6.67547.57%Hold
LRMRLarimar Therapeutics$6.08$20.33234.38%Buy
STOKStoke Therapeutics$11.31$30.60170.56%Buy
CGEMCullinan Oncology$12.58$31.50150.40%Buy
MLYSMineralys Therapeutics$12.60$30.00138.10%Buy
KZRKezar Life Sciences$7.49$17.50133.64%Buy
FHTXFoghorn Therapeutics$7.86$16.33107.76%Buy
KROSKeros Therapeutics$54.14$102.6089.51%Buy
DSGNDesign Therapeutics$5.48$9.6776.46%Buy
BOLTBolt Biotherapeutics$0.57$1.0075.44%Hold
NRIXNurix Therapeutics$22.64$32.2042.23%Buy
KYMRKymera Therapeutics$44.05$51.5016.91%Buy
RVMDRevolution Medicines, Inc. Warrant$57.07$60.636.24%Buy
IKNAIkena Oncology$1.70$1.33-21.76%Buy

KZR Forecast FAQ

Is Kezar Life Sciences a good buy?

Yes, according to 3 Wall Street analysts, Kezar Life Sciences (KZR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of KZR's total ratings.

What is KZR's price target?

Kezar Life Sciences (KZR) average price target is $17.5 with a range of $14 to $21, implying a 133.64% from its last price of $7.49. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Kezar Life Sciences stock go up soon?

According to Wall Street analysts' prediction for KZR stock, the company can go up by 133.64% (from the last price of $7.49 to the average price target of $17.5), up by 180.37% based on the highest stock price target, and up by 86.92% based on the lowest stock price target.

Can Kezar Life Sciences stock reach $11?

KZR's average twelve months analyst stock price target of $17.5 supports the claim that Kezar Life Sciences can reach $11 in the near future.

What are Kezar Life Sciences's analysts' financial forecasts?

Kezar Life Sciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $6.67M (high $6.67M, low $6.67M), average EBITDA is $4M (high $4M, low $4M), average net income is $-672M (high $-652M, low $-691M), average SG&A $10.39M (high $10.39M, low $10.39M), and average EPS is $-9.207 (high $-8.939, low $-9.464). KZR's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-865M (high $-865M, low $-865M), average SG&A $0 (high $0, low $0), and average EPS is $-11.861 (high $-11.861, low $-11.861).

Did the KZR's actual financial results beat the analysts' financial forecasts?

Based on Kezar Life Sciences's last annual report (Dec 2023), the company's revenue was $7M, beating the average analysts forecast of $1.17M by 500.00%. Apple's EBITDA was $-111M, missing the average prediction of $700K by -16017.71%. The company's net income was $-102M, missing the average estimation of $-537M by -81.03%. Apple's SG&A was $26.54M, beating the average forecast of $1.82M by 1359.85%. Lastly, the company's EPS was $-0.0014, missing the average prediction of $-7.36 by -99.98%. In terms of the last quarterly report (Sep 2023), Kezar Life Sciences's revenue was $7M, beating the average analysts' forecast of $166.67K by 4099.99%. The company's EBITDA was $-25.527M, missing the average prediction of $100K by -25627.00%. Kezar Life Sciences's net income was $-23.103M, missing the average estimation of $-260M by -91.12%. The company's SG&A was $8.79M, beating the average forecast of $259.71K by 3284.11%. Lastly, the company's EPS was $-0.32, missing the average prediction of $-3.565 by -91.02%